Trial Profile
Safety and efficacy of TNF-inhibitors (adalimumab, infliximab and etanercept) in patients with rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2016 New trial record